Fact Source: Financial Supervisory Service DART / 2026-01-21
Disclosure Type: Preliminary Earnings Results based on Consolidated Financial Statements (Voluntary Disclosure)
💡 3-Second Summary
Samsung Biologics has announced its preliminary consolidated operating profit for the fourth quarter of 2025 at KRW 528.3B, marking a sharp 67.8% increase year-over-year. While operating profit decreased quarter-over-quarter, the full-year cumulative operating profit reached KRW 2.07T, showing fundamental top-line growth.
📊 1. [Key Disclosure Content & Major Figures Summary]
- Q4 2025 Preliminary Financial Performance (Unit: KRW Millions / %):
- Revenue: Q4 2025 KRW 1,285,706 (Up 2.2% QoQ / Up 35.3% YoY)
- Operating Profit: Q4 2025 KRW 528,251 (Down 16.6% QoQ / Up 67.8% YoY)
- Profit Before Tax: Q4 2025 KRW 574,579 (Down 13.3% QoQ / Up 59.4% YoY)
- Net Income: Q4 2025 KRW 453,050 (Down 8.7% QoQ / Up 74.1% YoY)
- Full-Year 2025 Cumulative Preliminary Performance (Unit: KRW Millions / %):
- Cumulative Revenue: KRW 4,556,972 (Up 30.3% compared to the prior year’s cumulative results)
- Cumulative Operating Profit: KRW 2,069,221 (Up 56.6% compared to the prior year’s cumulative results)
- Cumulative Net Income: KRW 1,614,330 (Up 55.2% compared to the prior year’s cumulative results)
- Corporate Spin-off Impact Details:
- The stated profit lines exclude the discontinued operations income (net profit) of Samsung Bioepis resulting from the corporate spin-off.
- Stated Bioepis discontinued operations profit lines: KRW 78.1B in Q3 2025 / KRW 56.9B in Q4 2025 / KRW 170.0B for the FY2025 full-year cumulative.
- Investor Notice: These figures represent preliminary metrics compiled before the completion of the external audit and are subject to change. Investors should reference the subsequent official “Submission of Audit Report.” The filing does not clarify the specific drivers behind quarterly performance fluctuations.
📈 2. [Expert View: What This Disclosure Means for Investors]
This regulatory filing outlines Samsung Biologics’ consolidated preliminary operational performance for Q4 2025 and the full fiscal year. The primary data point for global markets is the notable year-over-year expansion, with Q4 revenue rising 35.3% and operating profit surging 67.8% compared to Q4 2024. This confirms that the company’s baseline profit generation capacity has achieved structural expansion over the past year.
On a quarter-over-quarter basis, however, a divergence appears as revenue edged up by 2.2% while operating profit dropped by 16.6% compared to Q3 2025. Although the original disclosure text does not state the specific drivers behind this quarterly margin compression, investors may factor in temporary parameters such as seasonal cost allocations or factory maintenance schedules. Additionally, it is vital to note that these figures reflect core business operations, purposefully excluding discontinued earnings from the Samsung Bioepis spin-off. Because minor numbers adjustments remain possible during the final external audit review, global investors should track the upcoming statutory audit report for confirmation rather than drawing definitive short-term conclusions.
📝 Editor’s Comment (by K-STOCK Editor)
Applied Comment Style: Professional Insight
Samsung Biologics’ Q4 preliminary disclosure effectively logs a key milestone, confirming full-year consolidated operating profit crossing the KRW 2T threshold. Delivering a 67.8% year-over-year surge in quarterly operating profit (KRW 528.3B) alongside a 56.6% cumulative full-year expansion indicates that the company’s core manufacturing infrastructure continues to operate at a highly productive level. While quarterly operating profit experienced a brief pause compared to the previous quarter, the steady upward trajectory of top-line revenue confirms that underlying operational scaling remains intact. Given that these figures exclude the technical accounting layers of the Bioepis spin-off, global investors should maintain a measured approach and track the finalized metrics in the upcoming formal audit report before the general shareholders’ meeting.
📢 Disclaimer & Source Information
Source: This content has been newly structured and written based on official data submitted to the Financial Supervisory Service’s Electronic Disclosure System (DART).
Investment Risk Notice: This information is provided solely for informational and linguistic reference purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial responsibilities rest entirely with the individual investor.
Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.
